Introduction {#s1}
============

Lung cancer is the most common cause of cancer-related death worldwide in recent years ([@B1]). As computed tomography (CT) becomes the main means of screening for high-risk populations of lung cancer, the detection rate for small-size lung cancer has been increasing ([@B2]). The standard treatment for early-stage lung cancer is lobectomy with systematic lymph node dissection (LND) ([@B3]), but whether lobectomy with systematic LND is necessary for all these patients remains unclear. The sublobar resection (wedge resection and segmentectomy) has been used for early-stage NSCLC, especially for patients with impaired pulmonary function reserve ([@B4]). Moreover, compared with those who underwent systematic LND, patients that received selective LND also presented a lower incidence of perioperative complications and similar survival ([@B5], [@B6]). However, these sublevel surgical procedures would be more likely to cause tumor residual, since occult LNM occurred not rarely, even though in small-size NSCLC ([@B7]--[@B11]). Of possibly greater concern is the occurrence of micrometastases in histologically negative lymph nodes from early-stage NSCLC patients ([@B10]). Thus, developing reliable methods for evaluating the risk of LNM is of great importance, and would be helpful for decision making of medical management.

CT and positron emission tomography/computed tomography (PET/CT) are widely used for noninvasive nodal staging, but these methods have limited accuracy. Invasive node staging approaches, such as mediastinoscopy and endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA), may not be cost-efficient for small-size NSCLC patients. However, there is still no generally-accepted method for precisely evaluating the risk of LNM in early-stage NSCLC. The clinicopathological characteristics and risk factors associated with LNM remain unclear. We aimed to analyze the clinicopathological characteristics related to LNM and to develop and validate a cost-efficient dynamic nomogram for evaluating the risk of LNM in patients with small-size NSCLC.

Materials and Methods {#s2}
=====================

Patient Enrollment
------------------

From January 2013 to June 2019, NSCLC patients in Peking Union Medical College Hospital (PUMCH) were retrospectively reviewed ([Figure 1](#F1){ref-type="fig"}). The eligibility criteria were: (1) single cancer lesion; (2) ≤ 2 cm in maximal diameter on CT; (3) receiving lung resection (lobectomy or sublobar resection) with systematic LND; (4) complete pathological information; (5) not receiving neoadjuvant chemotherapy or radiotherapy before surgery. This study was approved by the Ethics Committee of Peking Union Medical College Hospital. All patients signed informed consent forms before operation.

![Flowchart of the patients for the training and validation cohorts.](fonc-10-01322-g0001){#F1}

Clinicopathological Characteristics
-----------------------------------

All clinical information, including gender, age, smoking status, and serum carcinoembryonic antigen (CEA), was collected before the operation. The CT were performed within 60 days before surgery, and the imaging features involved maximal tumor size, imaging density, and specific signs such as speculation, vessel convergence, lobulation, pleural indentation, and calcification. The CT images were reviewed by two thoracic surgeons and one radiologist independently. The final conclusion was made by consensus reading if disagreement occurred between them. The tumor imaging density was grouped into pure ground glass nodule (pGGN), mixed GGN (mGGN), and solid lesions. mGGN was defined as the presence of a solid component within the nodule at the mediastinal window level of CT. Then, the mGGN was further divided into two groups according to the ratio of the maximal diameter of the solid component to the maximal diameter of the tumor area (the cutoff value was set as 50%). The pathological findings were recorded from paraffin-embedded surgery specimens by pathological experts from PUMCH. Patients\' pathological N status was confirmed according to the 8th edition TNM Classification for lung cancer ([@B12]). The presence of lymphovascular invasion (LVI) and pleural invasion were also included.

Surgical Procedure
------------------

For patients with a tumor size \<8 mm, lung resection was considered for those with high risk of malignancy after follow-up or at the demand of patients. Sublobar resection (wedge resection or segmentectomy) was considered for patients with a peripheral pGGN tumor or those with poor lung function reserve or comorbidities. For others, standard lobectomy with systematic LND was recommended firstly. In addition to N~1~ nodes (\#10, \#11, \#12, \#13, and \#14), systematic LND included 2R, 4R, 3A, 3P, \#7, \#8, and \#9 for tumors located in the right lung and 4L, \#5, \#6, \#7, \#8, and \#9 for tumors located in the left lung, if possible.

Statistical Analysis
--------------------

Patients were randomly divided into a training cohort and a validation cohort as a ratio of 7:3. Using the training cohort, the least absolute shrinkage and selection operator (LASSO) regression was performed to select optimal predictive variables for LNM. Then the logistic regression models were constructed by incorporating these variables. The models\' performance in both the training cohort and validation cohort included discrimination and calibration. Discrimination is the predictive accuracy to distinguish patients with LNM from those without LNM and can be measured by the area under the receiver operating characteristic (ROC) curve (AUC). Calibration curves were plotted using 1,000 bootstrap resamples, which reflected the model\'s agreement between the predicted probability and the actual probability. Decision curve analysis (DCA) was used to assess the model\'s clinical usefulness. Based on the logistic regression model, a dynamic nomogram was developed, presenting a specific system for calculating the risk of LNM.

Continuous data were expressed as median with interquartile (IQR). Statistical analysis was performed using IBM SPSS 25.0 (SPSS Inc; Chicago, IL, USA) and R software version 3.6.3. Pearson\'s Chi square test was used for categorical data analysis (Fisher exact test was used if necessary), while Mann--Whitney *U*-test were used to compare quantitative parameters. *P* \< 0.05 were considered statistically significant. All statistical analyses were two-sided.

Results {#s3}
=======

Patient Characteristics
-----------------------

A total of 1,102 patients met the inclusion criteria, including 403 males and 699 females. Among them, 116 patients (10.5%) were node-positive (pN~+~), and 986 (89.5%) had no lymph node metastasis (pN~0~) by final histopathology. The median age was 58 (IQR: 51--65) years, and the median tumor size on CT was 1.3 (IQR: 1.0--1.7) cm. Lobectomy was performed for 870 patients and sublobar resection for 232 patients. The two cohorts\' data of demographic characteristics and variables are shown in [Table 1](#T1){ref-type="table"}. The training cohort consisted of 774 (71.6%) patients, while the validate cohort included 328 (28.4%) patients. The LNM rate was 12.0% (83/774) in the training cohort vs. 10.1% (33/328) in the validation cohort (*P* = 0.743). The two cohorts were similar in most of characteristics except smoking history (*P* = 0.049) and imaging density (*P* = 0.039), the distribution of which were with slightly significant difference.

###### 

Demographic and clinicopathological characteristics in the training and validation cohorts.

  **Characteristic**        **Total**             **Training**          **Validation**        ***P*-value**
  ------------------------- --------------------- --------------------- --------------------- ---------------
  **LNM**                                                                                     
   Positive                 116                   83 (71.6)             33 (28.4)             0.743
   Negative                 986                   691 (70.1)            295 (29.9)            
  **Age, years**                                                                              
    \<58 (median)           525                   379 (72.2)            146 (27.8)            0.176
   ≥58                      577                   395 (68.5)            182 (31.5)            
  **Sex**                                                                                     
   Male                     403                   294 (73.0)            109 (27.0)            0.134
   Female                   699                   219 (68.7)            480 (31.3)            
  **Smoking history**                                                                         
   Yes                      218                   165 (75.7)            53 (24.3)             0.049
   No                       884                   609 (68.9)            275 (31.1)            
  **Tumor location**                                                                          
   Left                     641                   459 (71.6)            182 (28.4)            0.241
   Right                    461                   315 (68.3)            146 (31.7)            
  **Imaging density**                                                                         
   pGGN                     431                   284 (65.9)            147 (34.1)            0.039
   mGGN                     476                   346 (72.7)            130 (27.3)            
   SN                       195                   144 (73.8)            51 (26.2)             
  **Spiculation sign**                                                                        
   Present                  587                   415 (70.7)            172 (29.3)            0.72
   Absent                   515                   359 (69.7)            156 (30.3)            
  **VCS**                                                                                     
   Present                  234                   162 (69.2)            72 (30.8)             0.705
   Absent                   868                   612 (70.5)            256 (29.5)            
  **Lobulation sign**                                                                         
   Present                  403                   297 (73.7)            106 (26.3)            0.056
   Absent                   699                   477 (68.2)            222 (31.8)            
  **Pleural indentation**                                                                     
   Present                  294                   214 (72.8)            80 (27.2)             0.263
   Absent                   808                   560 (69.3)            248 (30.7)            
  **Calcification sign**                                                                      
   Present                  22                    17 (77.3)             5 (22.7)              0.466
   Absent                   1,080                 757 (70.1)            323 (29.9)            
  **Histological type**                                                                       
   ADC                      1056                  739 (70.0)            317 (30.0)            0.375
   Non-ADC                  46                    35 (76.1)             11 (23.9)             
  **LVI**                                                                                     
   Present                  31                    24 (70.0)             7 (30.0)              0.375
   Absent                   1,071                 750 (77.4)            321 (22.6)            
  **Pleural invasion**                                                                        
   Present                  109                   78 (71.6)             31 (28.4)             0.75
   Absent                   993                   696 (70.1)            297 (29.9)            
  **Surgical procedure**                                                                      
   Sublobar resection       232                   162 (69.8)            70 (30.2)             0.878
   Lobectomy                870                   612 (70.3)            258 (29.7)            
  Tumor size                1.3 \[1.0--1.7\]      1.3 \[1.0--1.7\]      1.3 \[1.0--1.6\]      0.344
  CEA, ng/ml                1.89 \[1.33--2.55\]   1.89 \[1.30--2.61\]   1.89 \[1.36--2.47\]   0.639

*LNM, lymph node metastasis; pGGN, pure ground glass nodule; mGGN, mixed GGN; SN, solid nodule; VCS, vessel convergence sign; ADC, adenocarcinoma; LVI, lymphovascular invasion; CEA, carcinoembryonic antigen*.

Variable Selection for Constructing Models
------------------------------------------

Using LASSO regression in the training cohort, 15 variables in [Table 1](#T1){ref-type="table"} were reduced to 6 when using 1 standard error (1--SE) criterion, and reduced to 11 when using the minimum error criterion ([Figure 2](#F2){ref-type="fig"}). Then two logistic regression models, which were marked as Model1 and Model2, were developed by incorporating the 6 variables and 11 variables in the training cohort, respectively. The details for selected variables are shown in [Table 2](#T2){ref-type="table"}, including tumor size (OR: 3.889, 95%CI: 1.878--8.052, *P* \< 0.001), CEA (OR: 1.247, 95%CI: 1.110--1.402, *P* \< 0.001), imaging density, histology (OR: 3.583, 95%CI: 1.466--8.757, *P* = 0.005), lymphovascular invasion (OR: 11.979, 95%CI: 4.479--32.039, *P* \< 0.001), and pleural invasion (OR: 2.406, 95%CI: 1.223--4.731, *P* \< 0.001).

![Variable selection using the least absolute shrinkage and selection operator (LASSO) regression model. **(A)** The selection of optimal predictive variables by 5-fold cross-validation. The left and right dotted vertical lines represent the optimal values of lambda when using the minimum criterion and the one-fold standard error of minimum criterion, respectively. **(B)** LASSO coefficients of the 15 variables.](fonc-10-01322-g0002){#F2}

###### 

The logistic regression models using the selected optimal predictive variables in the training cohort.

           **Variable**                  **Coefficient**   **OR (95%CI)**           ***P*-value**
  -------- ----------------------------- ----------------- ------------------------ ---------------
  Model1   Size, cm                      1.358             3.889 (1.878--8.052)     \<0.001
           CEA, ng/ml                    0.221             1.247 (1.110--1.402)     \<0.001
           Imaging density (Ref: SN)                                                
           pGGN                          −18.433           \<0.001                  0.994
           mGGN                          0.362             1.436 (0.772--2.669)     0.253
           Non-ADC (Ref: ADC)            1.276             3.583 (1.466--8.757)     0.005
           LVI                           2.483             11.979 (4.479--32.039)   \<0.001
           Pleural invasion              0.878             2.406 (1.223--4.731)     0.011
  Model2   Size, cm                      1.732             5.655 (2.623--12.190)    \<0.001
           CEA, ng/ml                    0.234             1.263 (1.119--1.426)     \<0.001
           Imaging density (Ref: SN)                                                0.588
           pGGN                          −18.622           \<0.001                  0.994
           mGGN                          0.335             1.398 (0.739--2.644)     0.303
           Non-ADC (Ref: ADC)            1.153             3.169 (1.243--8.079)     0.016
           LVI                           2.789             16.26 (5.654--46.763)    \<0.001
           Pleural invasion              1.043             2.837 (1.385--5.810)     0.004
           Age ≥ 58, years (Ref: \<58)   0.683             1.981 (1.108--3.541)     0.021
           Spiculation sign              −0.351            0.704 (0.355--1.393)     0.313
           VCS                           −0.545            0.580 (0.259--1.300)     0.186
           Lobulation sign               −0.207            0.813 (0.425--1.554)     0.531
           Pleural indentation           −0.350            0.705 (0.365--1.361)     0.298

*CEA, carcinoembryonic antigen; SN, solid nodule; pGGN, pure ground glass nodule; mGGN, mixed GGN; ADC, adenocarcinoma; LVI, lymphovascular invasion; VCS, vessel convergence sign. Ref, reference*.

Model Validation
----------------

To assess the predictive ability of models, the ROC curves in both the training cohort and validation cohort were plotted ([Figure 3](#F3){ref-type="fig"}). In the training cohort, the AUC for Model1 was 0.895 (95%CI: 0.866--0.925), similar to 0.907 (95%CI: 0.880--0.934) for Model2 (*P* = 0.171; [Figure 3A](#F3){ref-type="fig"}). However, Model1 (AUC = 0.931, 95%CI: 0.896--0.967) performed significantly better than Model2 (AUC = 0.915, 95%CI: 0.875--0.955) in the validation cohort (*P* = 0.047; [Figure 3B](#F3){ref-type="fig"}). In addition, decision curve showed that two models presented similar net benefits at the entire range of threshold probabilities, with the better performance than the two extreme lines (treat-none and treat-all) when the threshold probability was 0--0.8 ([Figure 4](#F4){ref-type="fig"}). Thus, with fewer variables incorporated, Model1 was selected as a better model and used to develop a nomogram for calculating the risk of LNM ([Figure 5](#F5){ref-type="fig"}). Then calibration curves were plotted for internal and external validation, showing the great calibration of the nomogram model in both training and validation cohorts ([Figure 6](#F6){ref-type="fig"}). Additionally, a dynamic nomogram application (<https://nomogramwyj.shinyapps.io/27978155ff984a9f9616812a465b802c>) was also developed, which can be conveniently available to clinicians and patients worldwide. Using the application, one patient\'s risk probability plus 95%CI of LNM can be obtained immediately when imputing his information of the six variables we identified (shown in [Supplement Figure 1](#SM2){ref-type="supplementary-material"}). The R code and data for the application were attached in [Supplement Data Sheet 1](#SM1){ref-type="supplementary-material"}.

![Receiver operating characteristic (ROC) curves of Model1 and Model2 for predicting lymph node metastasis in the training and validation cohorts. **(A)** ROC curve in the training cohort. Area under ROC curve (AUC): 0.895 (95%CI: 0.866--0.925; sensitivity: 80.7%, specificity: 81.2%) in Model 1 vs. 0.907 (95%CI: 0.880--0.934; sensitivity: 85.5%, specificity: 80.6%) in Model2 (*P* = 0.171). **(B)** ROC curve in the validation cohort. AUC: 0.931 (95%CI: 0.896--0.967; sensitivity: 97.0%, specificity: 76.6%) in Model1 vs. 0.915 (95%CI: 0.875--0.955; sensitivity: 93.9%, specificity: 75.6%) in Model2 (*P* = 0.047).](fonc-10-01322-g0003){#F3}

![Decision curve for Model1 and Model2. The treat-all line represents the net benefits of giving all patients lobectomy with systematic lymph node dissection, and the treat-none line represents the net benefits of giving no patient the above-mentioned surgical procedure.](fonc-10-01322-g0004){#F4}

![The nomogram for predicting the risk of lymph node metastasis in patients with NSCLC ≤ 2 cm, based on six clinicopathological variables (tumor size, CEA, histological type, imaging density, LVI, PI). CEA, carcinoembryonic antigen; ADC, adenocarcinoma; pGGN, pure ground glass nodule; mGGN, mixed GGN; SN, solid nodule; LVI, lymphovascular invasion; PI, pleural invasion.](fonc-10-01322-g0005){#F5}

![Calibration curves for the nomogram model in the training cohort **(A)** and validation cohort **(B)**.](fonc-10-01322-g0006){#F6}

Based on the nomogram model, each patient\'s risk probability of LNM was calculated. The optimal cutoff point to distinguish between LNM (--) and LNM (+) was 0.092. All patients\' predictive risk probabilities from the nomogram was standardized using the following formula: (risk probability−0.092)/standard deviation. Then the standardized risk of each patient was shown in [Figure 7](#F7){ref-type="fig"}. The *x*-axis represents each patient, while *y*-axis represents the standardized risk probabilities from the nomogram.

![Standardized predictive risk probabilities of LNM calculated by the nomogram for all patients. LNM, lymph node metastasis.](fonc-10-01322-g0007){#F7}

Discussion {#s4}
==========

In this study, single NSCLC ≤ 2 cm were retrospectively reviewed for the development and validation of a dynamic nomogram for evaluating the risk of LNM in small-size NSCLC. To our knowledge, this study was the first one to develop a dynamic nomogram for the evaluation of LNM in lung cancer. For patients whose tumors were staged as T~1~N~0~M~0~, the standard therapy has been considered as lobectomy with systematic LND ([@B3]). In recent years, with the rapid development and employment of radiographical screening methods, increasing numbers of small-size lung carcinomas have been discovered. Several studies have reported no significant difference in survival between patients with stage I NSCLC who underwent sublobar resection (wedge resection and segmentectomy) and standard lobectomy, especially for NSCLC ≤ 2 cm ([@B4], [@B13], [@B14]). SABR ([@B15]) and RFA ([@B16]), which have also become alternative treatments for small-size NSCLC, might be more appropriate for elderly or inoperable patients than surgery. However, compared to standard lobectomy, sublobar resection and other alternatives might lead to a higher risk of recurrence and a worse survival ([@B17]); one reason for this difference might be attributed to occult LNM and micrometastasis, which were not rare in small-size NSCLC ([@B7]--[@B11]). According to studies from Shi et al. ([@B18]) and Yu et al. ([@B19]) the incidence rates of LNM in NSCLC ≤ 2 cm were up to 14.1 and 10.2%, respectively, which were similar to the result in our study (10.5%, 116/1,102). Therefore, it is necessary to evaluate the risk of LNM in patients with small-size NSCLC. The reliable predictive methods are highly required.

Unlike the conventional univariate analysis, LASSO regression that we used aimed to select variables for logistic regression to avoid overfitting. Then two models were developed with different number of variables. Both of models presented very high AUCs in ROC curves ([Figure 3](#F3){ref-type="fig"}) and similar clinical usefulness in the decision curve ([Figure 4](#F4){ref-type="fig"}). The Model1, with much fewer variables incorporated, was used to plot the nomogram. The nomogram was a novel cost-efficient tool for precisely calculating the risk of LNM ([Figure 5](#F5){ref-type="fig"}). It has a user-friendly interface and is very convenient to apply in helping making clinical decisions. Our nomogram model was also well-calibrated in both internal and external validation ([Figure 6](#F6){ref-type="fig"}), with the mean absolute error of 0.01 and 0.02, respectively. Thus, based on the nomogram, each patient\'s risk for LNM can be accurately calculated according to the six variables, which were tumor size, CEA level, imaging density, pathological type of NSCLC (adenocarcinoma or non-adenocarcinoma), lymphovascular invasion and pleural invasion.

Previously, our ([@B20]) and other studies ([@B19], [@B21]--[@B23]) have found that several preoperative factors might be associated with the occurrence of LNM in small-size NSCLC, including serum CEA, tumor size and imaging features such as imaging density. Tumor size was identified as an important predictor for LNM. The incidence rate of LNM increased as tumor size increased. In our nomogram model, the larger tumor size (OR: 3.889, 95%CI: 1.878--8.052, *P* \< 0.001) was an independent risk factor for LNM. Okada et al. ([@B24]) thought of tumor size as a predictor for sublobar resection, but in our study, only those patients with tumors ≤ 0.5 cm were not found to have positive nodes. It is not advisable to choose surgical procedure and postoperative management solely by tumor size. Other factors should be considered. Similar to previous studies ([@B19], [@B22]), a higher serum CEA (OR: 1.247, 95%CI: 1.110--1.402, *P* \< 0.001) was also associated with a higher LNM rate in our study. Thus, the serum CEA level might be helpful for LNM prediction and should be listed as a routine test for NSCLC patients. In addition, tumor imaging density was also considered to be an important risk factor for LNM since none of the patients with a pGGN tumor were found to be node-positive in our study. The solid component on CT has been confirmed as having a more invasive ability for lung tumors and indicated a significantly higher LNM rate than pGGN ([@B21]), which was further consolidated by our study. Therefore, pGGN can be a strongly effective predictor for node negativity in small-size NSCLC.

Moreover, this study also indicated that pathology had a strong association with LNM in patients with small-size NSCLC. Non-adenocarcinomas (OR: 3.583, 95%CI: 1.466--8.757, *P* = 0.005) were more likely to have LNM than adenocarcinomas, although there were only limited quantities of their cases. Furthermore, the presence of lymphovascular invasion (OR: 11.979, 95%CI: 4.479--32.039, *P* \< 0.001) and pleural invasion (OR: 2.406, 95%CI: 1.223--4.731, *P* \< 0.001) significantly indicated LNM. Therefore, when lymphovascular invasion or pleural invasion was present, even if the histological results showed the dissected lymph nodes were negative, surgeons should be more alert to the occurrence of LNM. If possible, pathologists might observe these characteristics intraoperatively and help surgeons make decisions of surgical procedure, especially for those patients who are difficult to decide between radical and sublevel resection.

Our previous study developed machine learning-based models for the preoperative prediction of LNM ([@B20]), but the LNM status should be furtherly evaluated after surgery, with considering histology, especially for patients with negative nodes. The current surgery methods cannot guarantee the removal of all tumor cell-invaded lymph nodes. Additionally, with the increasing application of sublevel resection, the undetected occult LNM and micrometastasis might occur more frequently, likely to cause recurrence and worse survival. Furthermore, the advanced immunotherapy for NSCLC patients may require an accurate N stage, since a discrepant programmed death-ligand 1 (PD-L1) expression was observed between primary tumors and nodal metastases of NSCLC ([@B25]). The small-size NSCLC patients with nodal metastases are the potential population that may benefit from adjuvant immunotherapy, and the nomogram we developed can be helpful for identifying optimal candidates for immunotherapy. Thus, based on our nomogram model, the patients with high risk of LNM could be precisely selected for closer postoperative follow-up and timely medical intervention, which might improve prognosis.

In addition, some methodological innovations were indicated in our study. The nomogram was rarely used to predict LNM in lung cancer. Jiang et al. ([@B26]) developed a nomogram for predicting occult N2 LNM in squamous cell lung cancer, but the number of cases was very limited and only involved squamous carcinomas. Some previous studies have developed nomogram models using radiomics for predicting LNM ([@B27], [@B28]). However, identifying radiomics features requires special techniques, and the radiomics models are hard to be clinically applied. The dynamic nomogram we developed was based on clinicopathological characteristics that were routinely recorded, and was easily to use for clinicians. To our knowledge, this study was the first nomogram model for evaluating the risk of LNM in NSCLC based on relevant clinicopathological characteristics, and we also developed a dynamic nomogram application for clinicians and patients to use worldwide. Moreover, other than conventional univariate analysis, LASSO regression was used to select optimal predictive variables, which effectively performed well in reducing the dimension of data ([@B29], [@B30]). Finally, besides the internal validation, the external validation was also used to assess the model\'s calibration, since there was a large enough number of patients.

Furthermore, the potential limitations of our study should be noted. First, this study cohort only consisted of patients from a single center, which was not representative of patients in other hospitals. A more accurate nomogram should be developed using data from multiple centers in the future. Second, in spite of undergoing systematic LND, a small group of patients received sublobar resection, which might lead to the underestimate of positive N1 rate. We will conduct further research on their difference. Thirdly, our study did not involve all clinicopathological characteristics. In our previous ([@B20]) and other studies ([@B31]), maximal standardized uptake value (SUV~max~), was proved to be an impressive predictive factors for LNM, but was not included. That is because PET scan was not routinely performed for small-size NSCLC, and the variable with many missing values was not suitable for linear regression. Future studies may consider all clinicopathological characteristics as much as possible for developing a globally-applicable nomogram.

Conclusions {#s5}
===========

Based on clinicopathological characteristics, this study firstly developed a cost-effective dynamic nomogram for calculating the precise risk of LNM in small-size NSCLC, and will be helpful for clinicians\' decision-making.
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